Search Results - chung-jen (james) chou

3 Results Sort By:
Mitochondrial targeted HDAC inhibitors for the treatment of heart failure and related diseases and disorders (MitoDACs)
Mitochondrial targeted HDAC inhibitors for the treatment of heart failure and related diseases and disorders (MitoDACs)Technology: Researchers at MUSC have discovered HDAC1 is present in the adult cardiac myocyte mitochondria. A series of HDAC1 inhibitors that target mitochondria have been made (MitoDACs). One of the analog, LL-66, localizes to the...
Published: 8/22/2017   |   Inventor(s): Donald Menick, Chung-Jen (James) Chou, Daniel Herr, Xiaoyang Li
Keywords(s):  
Category(s): Therapeutic
Novel class I HDAC inhibitors that are impervious to glucuronidation for the treatment of hematologic malignancies and inflammatory diseases/disorders
MUSC researchers have developed a series of potent and selective class I histone deacetylase (HDAC) inhibitors. Currently, approved HDAC inhibitors are generated using hydroxamic acid or a benzylic amine motif and suffer from toxicity, off-target effects, and metabolic inactivation. Furthermore, the first generation HDAC inhibitors have been shown...
Published: 2/1/2017   |   Inventor(s): Chung-Jen (James) Chou, Jesse McClure, Cheng Zhang, Elizabeth Inks
Keywords(s):  
Category(s): Therapeutic
Therapeutics for Epilepsy and other Neurological Disorders
The inventors discovered a novel non-toxic agent that attenuates seizure activity in two animal models of epilepsy. This agent is a highly potent Vitamin K analogue that was first identified in a chemical screen using a zebrafish model of epilepsy (Figure 1). This agent was further tested in several mouse models of epilepsy, performed at the NIH An...
Published: 3/27/2013   |   Inventor(s): Chung-Jen (James) Chou, Sherine Chan, Jennifer Rahn, Benjamin Josey
Keywords(s): neurological
Category(s): Therapeutic
© 2018. All Rights Reserved. Powered by Inteum